Trial Profile
Effects of a Melatonin Receptor Agonist on Clinical Manifestations and Peripheral Biological Markers of Circadian Rhythm
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2022
Price :
$35
*
At a glance
- Drugs Ramelteon (Primary)
- Indications Generalised anxiety disorder; Insomnia; Major depressive disorder
- Focus Biomarker; Therapeutic Use
- 07 Oct 2022 Status changed from recruiting to completed.
- 15 Feb 2018 New trial record